PriceTargets.com logo

Zosano Pharma - ZSAN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 12/9/2022 01:00 AM ET
+0 (0.00%)
Get New Zosano Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZSAN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZSAN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Zosano Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.00.

This chart shows the closing price for ZSAN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Zosano Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2022Maxim GroupDowngradeBuy ➝ HoldMedium
2/23/2022BTIG ResearchDowngradeBuy ➝ NeutralHigh
7/30/2021HC WainwrightReiterated RatingBuy$70.00Medium
3/15/2021Maxim GroupBoost TargetBuy$52.50 ➝ $87.50Low
11/25/2020HC WainwrightLower TargetBuy$87.50 ➝ $70.00Low
10/22/2020BTIG ResearchLower TargetBuy$245.00 ➝ $70.00Low
10/2/2020Maxim GroupReiterated RatingBuy$70.00Low
10/2/2020HC WainwrightLower TargetBuy$140.00 ➝ $87.50Low
6/15/2020HC WainwrightReiterated RatingBuy$140.00High
5/20/2020Maxim GroupReiterated RatingBuyMedium
5/15/2020HC WainwrightReiterated RatingBuy$140.00Medium
4/19/2020HC WainwrightInitiated CoverageBuy$140.00Low
4/9/2020HC WainwrightInitiated CoverageBuy$140.00High
3/28/2020Maxim GroupReiterated RatingBuy$70.00Low
3/27/2020BTIG ResearchLower TargetBuy$560.00 ➝ $245.00Medium
3/7/2020Maxim GroupReiterated RatingBuy$70.00High
11/15/2019Maxim GroupReiterated RatingBuy$280.00Low
11/15/2019Cantor FitzgeraldLower TargetOverweight$420.00 ➝ $210.00Low
11/15/2019BTIG ResearchLower TargetBuy ➝ In-Line$560.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Zosano Pharma logo
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Read More

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: $3.90
Low: $0.52
High: $112.00

52 Week Range

Now: $0.00
Low: $0.46
High: $37.45

Volume

5,685 shs

Average Volume

425,375 shs

Market Capitalization

$980.40

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Zosano Pharma?

The following Wall Street sell-side analysts have issued research reports on Zosano Pharma in the last twelve months:
View the latest analyst ratings for ZSAN.

What is the current price target for Zosano Pharma?

0 Wall Street analysts have set twelve-month price targets for Zosano Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Zosano Pharma in the next year.
View the latest price targets for ZSAN.

What is the current consensus analyst rating for Zosano Pharma?

Zosano Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ZSAN.

What other companies compete with Zosano Pharma?

Other companies that are similar to Zosano Pharma include OncoSec Medical, Viveve Medical, Kaleido Biosciences, Context Therapeutics and Grifols. Learn More about companies similar to Zosano Pharma.

How do I contact Zosano Pharma's investor relations team?

Zosano Pharma's physical mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company's listed phone number is (510) 745-1200 and its investor relations email address is [email protected]. The official website for Zosano Pharma is www.zosanopharma.com. Learn More about contacing Zosano Pharma investor relations.